Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Receives Major Grant for Anti-Cancer Drug Study

JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman.

Cetuximab, also known by its brand name ERBITUX®, is currently indicated either as a single agent or in combination for the treatment of patients who have metastatic colorectal cancer. It is also approved for the treatment of a certain type of locally or regionally advanced head and neck cancer. Cetuximab binds to the EGFR on the surface of the cancer cells, thus interfering with their growth. EGFR is part of a signaling pathway involved in many types of human cancers, including head and neck, lung, esophagus, stomach, colon, rectum and many others.

The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers and helps to establish collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer.

“We are pleased to collaborate with NCCN by supporting this important research,” said Eric Rowinsky, M.D., Senior Vice President and Chief Medical Officer, ImClone Systems Incorporated. “Clinical research that brings together the expertise of such esteemed institutions can only improve outcomes for patients with cancer.”

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

The NCCN Member Institutions are:

  • Abramson Cancer Center at the University of Pennsylvania
  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope National Medical Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • O'Neal Comprehensive Cancer Center at UAB
  • Roswell Park Comprehensive Cancer Center
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • UC San Diego Moores Cancer Center
  • UCLA Jonsson Comprehensive Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Rogel Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • UT Southwestern Simmons Comprehensive Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital